The results are consistent with studies which showed that measures of endogenous insulin secretion were inversely associated with the presence of sarcopenia in individuals with type 2 diabetes (28) and that insulin treatment attenuates skeletal muscle mass loss (21, 22). Here, INS is linked to sarcopenia.